Failure of B7.1-modified tumor to evoke full activation of CD8+ tumor-infiltrating lymphocytes in the central nervous system: Prevention of parental tumor growth in the subcutaneous environment

Journal of Neurosurgery

Volumn 97, Issue 2, 2002, Pages 432-440

  Ando, Hiromichi ^a   Saio, Masanao ^a   Tamakawa, Noriyuki ^a   Ohe, Naoyuki ^a   Nakayama, Takashi ^a   Yu, Hai ^a   Kaku, Yasuhiko ^a   Iwama, Toru ^a   Shinoda, Jun ^a   Sakai, Noboru ^a   Takami, Tsuyoshi ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antitumor immunity; Central nervous system; Cytotoxic T cell; Intracranial lymphoma model; Mouse

Indexed keywords

B7 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER GRAFT; CANCER SURVIVAL; CELL ISOLATION; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; DNA MODIFICATION; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GROWTH INHIBITION; IMMUNOPATHOLOGY; LYMPHOCYTE COUNT; LYMPHOMA CELL LINE; MAGNETIC SEPARATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; VACCINATION;

EID: 0036320814     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.2002.97.2.0432     Document Type: Article

References (41)

1. Characterization of human inducible costimulator ligand expression and function
2. Tumor antigen presentation: Changing the rules
3. Gene therapy for brain tumors
4. A role for CD95 ligand in preventing graft rejection
5. CD28 and apoptosis
6. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation
7. Co-stimulation in T cell responses
8. B7-H3: A costimulatory molecule for T cell activation and IFN-gamma production
9. Anti-tumor gene therapy
10. B7-1 and interleukin 12 synergistically induce effective antitumor immunity
11. The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function
12. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status
13. Adoptive transfer of cytotoxic T lymphocytes induced by CD86-transfected tumor cells suppresses multi-organ metastases of C1300 neuroblastoma in mice
14. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice
15. Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation
16. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
17. Autoimmunity in the eye and its regulation
18. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2
19. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules
20. Generation of cytotoxic immune responses during the progression of a rat glioma
21. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
22. Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12
23. PD-L2 is a second ligand for PD-I and inhibits T cell activation
24. CD28/B7 system of T cell costimulation
25. The role of the CD28 receptor during T cell responses to antigen
26. Adoptive immunotherapy of intracerebral metastases in mice
27. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: Effects on tumorigenicity, metastatic potential and immune response
28. Immunity to homologous grafted skin: III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye
29. B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity
30. + tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ
31. The central effectors of cell death in the immune system
32. + cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system
33. Postoperative immuno-gene therapy of murine bladder tumor by in vivo administration of retroviruses expressing mouse interferon-gamma
34. Unraveling immune privilege
35. Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-gamma, interleukin-7, or B7-1-transfected tumor cells
36. Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta
37. A reassessment of the role of B7-1 expression in tumor rejection
38. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA- 4 costimulatory molecules
39. B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas
40. T-cell co-stimulation through B7RP-1 and ICOS
41. Characterization of a new human B7-related protein: B7RP-1 is the ligand to the costimulatory protein ICOS